Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of E...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

LabPsycho Sep. 8 at 2:59 PM

$VSTM $ERAS Verastem Oncology and Erasca evaluating VS-7375 in combination with ERAS-0015, Erasca's investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors. This could be very interesting combo IMO. Plus VSTM upcoming clinical update + investor conferences = likely updraft on stock price. Cons = overall market and stock price already doubled. Could VSTM run like ERAS and TNGX and GLUE did the past 16 months?

0 · Reply

Cheesyisi Sep. 7 at 4:13 PM

$ERAS

0 · Reply

kdawg1 Sep. 4 at 4:59 PM

$ERAS This just seems to be another biotech where you sell after the good news as the next scheduled big news is not til 2027. Buy back in January.

0 · Reply

zzzdoc01 Sep. 3 at 10:12 PM

$ERAS 🤡

0 · Reply

profitraider Sep. 2 at 7:15 PM

$ERAS Boyz… nowhere to go but down!

0 · Reply

Cheesyisi Sep. 2 at 6:20 PM

$ERAS why the drop?

0 · Reply

Alt_Fuel Sep. 2 at 12:23 PM

$VSTM $RVMD $ERAS BOSTON--(BUSINESS WIRE)--Sep. 2, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: - Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET - H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

0 · Reply

Floridaorange Sep. 1 at 3:34 PM

$ERAS ngen definitely worth your time too. Glta

0 · Reply

Quantumup Aug. 28 at 12:50 PM

Guggenheim⬆️ $RVMD's PT to $275 vs $240 and stays Buy $IMRX $ERAS TNGX BBOT ANL VSTM Guggenheim models $294M net product sales in 2H26 vs. consensus of $116M, and $1.1B in 2027 up from $970M—continues to recommend the stock with a BUY rating as it sees high potential (pot'l) for a strong product launch, achievable Street consensus expectations, as well as a busy pipeline catalyst path. Next up: Guggenheim expects to gain more visibility on RVMD's pot'l pipeline development strategy in metastatic colorectal cancer (mCRC) during 4Q26, representing another pot'l major source of upside, while the Co. is enrolling 7 add'l Phase 3 studies that will start to generate data in 2027—also looks for first PoC data for RMC-5127 (RAS G12V) and RM-055 (next-gen. RAS[ON] inhibitor) during 2027—plus believes there is pot'l for early regulatory US-approval of zoldonrasib in 2027, should RVMD pursue an accelerated approval strategy in NSCLC.

1 · Reply

Quantumup Aug. 28 at 11:28 AM

UBS⬆️ $RVMD's PT to $265,⬆️peak sales to $14.4B, keeps at Buy and said -- We are increasing our PT to $265 from $220 by adjusting to the announced price of daraxonrasib and increasing our 2026 and 2027 sales estimates for daraxonrasib. $IMRX $ERAS TNGX BBOT ANL VSTM UBS added —We have also increased the probability of success (PoS) to 100% following the drug's approval. Given these changes, we believe a higher multiple is warranted, as they increase our confidence in both the commercial outlook for the product and our overall investment thesis for the company. We now value RVMD at 3.7x EV/2035 peak sales (vs. 3.5x prior) of $14.4B vs. $12.3B prior. Our 3.7x multiple is supported by our DCF sensitivity analysis and at the higher range of comparable companies.

0 · Reply

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Sep 8, 2026, 7:00 AM EDT - 5 days ago

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 2, 2026, 12:31 PM EDT - 11 days ago

Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims

2026-08-27T13:10:18.000Z - 17 days ago

Erasca price target raised to $33 from $25 at JPMorgan

2026-08-24T12:10:17.000Z - 20 days ago

Erasca granted Fast Track Designation for ERAS-0015

Aug 24, 2026, 8:00 AM EDT - 20 days ago

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

2026-08-17T10:17:45.000Z - 27 days ago

Erasca price target raised to $22 from $18 at H.C. Wainwright

2026-08-17T08:10:28.000Z - 27 days ago

Erasca price target raised to $21 from $20 at Guggenheim

2026-08-16T13:45:34.000Z - 4 weeks ago

Erasca price target raised to $20 from $18 at BofA

2026-08-11T20:12:29.000Z - 4 weeks ago

Erasca reports Q2 EPS (14c), consensus (11c)

Aug 11, 2026, 4:01 PM EDT - 4 weeks ago

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

Aug 11, 2026, 4:00 PM EDT - 4 weeks ago

Erasca Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 4 weeks ago

Erasca Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Erasca Slides: Corporate presentation

Aug 3, 2026, 12:30 PM EDT - 5 weeks ago

Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of an Upcoming Lead Plaintiff Deadline on August 10, 2026

Jul 30, 2026, 10:07 AM EDT - 6 weeks ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS

Jul 27, 2026, 3:45 PM EDT - 6 weeks ago

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

Jul 27, 2026, 2:49 PM EDT - 6 weeks ago

ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses

Jul 24, 2026, 9:45 AM EDT - 7 weeks ago

Kaplan Fox Reminds Erasca, Inc. (ERAS) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 10, 2026

2026-07-20T12:00:19.000Z - 7 weeks ago

Erasca price target raised to $21 from $12 at Morgan Stanley

Jul 15, 2026, 4:01 PM EDT - 1 month ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-14T20:00:14.000Z - 2 months ago

Erasca price target raised to $24 from $21 at Jefferies

2026-07-14T14:05:32.000Z - 2 months ago

Erasca 31.429M share Spot Secondary priced at $17.50

2026-07-14T12:20:48.000Z - 2 months ago

Erasca price target raised to $18 from $16 at BofA

Jul 13, 2026, 11:10 PM EDT - 2 months ago

Erasca Announces Pricing of Upsized Public Offering of Common Stock

2026-07-13T20:35:11.000Z - 2 months ago

Erasca $500M Spot Secondary being re-offered at $17.50

2026-07-13T20:25:18.000Z - 2 months ago

Erasca announces $500M common stock offering

2026-07-13T20:20:09.000Z - 2 months ago

Erasca files automatic mixed securities shelf

Jul 13, 2026, 4:19 PM EDT - 2 months ago

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

2026-07-13T20:10:54.000Z - 2 months ago

Erasca announces updated preliminary ERAS-0015 data

Jul 13, 2026, 4:01 PM EDT - 2 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

2026-07-13T09:30:11.000Z - 2 months ago

Erasca initiated with Early Stage Biotech at Goldman Sachs

Jul 3, 2026, 8:00 PM EDT - 2 months ago

ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role

Jul 2, 2026, 5:47 PM EDT - 2 months ago

ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jul 2, 2026, 8:20 AM EDT - 2 months ago

Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List

HOOD EHC EYPT MU ORCL

Jun 24, 2026, 9:24 AM EDT - 2 months ago

ERASCA, INC. (ERAS) INVESTOR ALERT Investors With Large Losses in Erasca, Inc. Should Contact Bernstein Liebhard LLP to Discuss Their Rights

Jun 4, 2026, 3:30 PM EDT - 3 months ago

Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset

2026-06-04T09:20:58.000Z - 3 months ago

Erasca upgraded to Neutral from Underperform at BofA

Jun 3, 2026, 3:10 PM EDT - 3 months ago

Erasca Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 3 months ago

Erasca to Present at the Jefferies Global Healthcare Conference

May 13, 2026, 6:00 PM EDT - 4 months ago

Erasca Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T12:45:19.000Z - 4 months ago

Erasca price target lowered to $26 from $28 at Mizuho

May 11, 2026, 4:01 PM EDT - 4 months ago

Erasca Reports First Quarter 2026 Business Updates and Financial Results

May 11, 2026, 4:00 PM EDT - 4 months ago

Erasca Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 4 months ago

Erasca Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

May 6, 2026, 8:00 AM EDT - 4 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Apr 30, 2026, 7:00 AM EDT - 4 months ago

Erasca Slides: Corporate presentation

Apr 28, 2026, 12:29 PM EDT - 4 months ago

Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off.

Apr 28, 2026, 10:22 AM EDT - 4 months ago

Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Erasca Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Erasca Proxy statement: Proxy filing

Apr 28, 2026, 6:13 AM EDT - 4 months ago

Erasca shares sink after patient death in early-stage cancer drug trial

Apr 27, 2026, 4:30 PM EDT - 4 months ago

Erasca Transcript: Study result

Apr 27, 2026, 4:30 PM EDT - 4 months ago

Erasca Press release: Study result

Apr 27, 2026, 4:30 PM EDT - 4 months ago

Erasca Slides: Study result

Apr 27, 2026, 4:01 PM EDT - 4 months ago

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Apr 27, 2026, 8:30 AM EDT - 4 months ago

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Mar 12, 2026, 4:01 PM EDT - 6 months ago

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Erasca Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Erasca Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Erasca Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

LabPsycho Sep. 8 at 2:59 PM

0 · Reply

Cheesyisi Sep. 7 at 4:13 PM

$ERAS

0 · Reply

kdawg1 Sep. 4 at 4:59 PM

$ERAS This just seems to be another biotech where you sell after the good news as the next scheduled big news is not til 2027. Buy back in January.

0 · Reply

zzzdoc01 Sep. 3 at 10:12 PM

$ERAS 🤡

0 · Reply

profitraider Sep. 2 at 7:15 PM

$ERAS Boyz… nowhere to go but down!

0 · Reply

Cheesyisi Sep. 2 at 6:20 PM

$ERAS why the drop?

0 · Reply

Alt_Fuel Sep. 2 at 12:23 PM

0 · Reply

Floridaorange Sep. 1 at 3:34 PM

$ERAS ngen definitely worth your time too. Glta

0 · Reply

Quantumup Aug. 28 at 12:50 PM

1 · Reply

Quantumup Aug. 28 at 11:28 AM

0 · Reply

Cohensha Aug. 27 at 8:48 PM

$CAPR $REPL $ERAS Any favorite Biotech "Fallen Angels" right now? 🧬📉 Lately, I’ve had solid wins buying biotechs right after a brutal 50%+ single-day crash (CRL or trial miss). The goal: catch market panic at rock-bottom prices, with downside cushioned by cash. Recent wins caught at the bottom: ERAS, REPL, and CAPR. How I filter the trash: * Cash Floor: Market cap near total cash (EV is basically zero, decent runway). * Not Dead Yet: Fixable CRL (CMC/labeling), strong subgroup data, or backup pipeline. * Unmet Need: Orphan diseases or severe targets where the FDA is more flexible. > ⚠️ High risk & wild volatility. Not financial advice—plenty of these end up diluting to zero. > Got any beaten-down names on your radar where the market overreacted? Drop your picks! 👇

2 · Reply

Quantumup Aug. 27 at 12:33 PM

H.C. Wainwright reiterated $IMRX Buy-$14 and said -- The first approval of a RAS-directed therapy in metastatic pancreatic cancer is an important milestone for the field, but we do not view it as weakening the atebimetinib thesis. $RVMD $ERAS TNGX BBOT ANL VSTM Here's what H.C. Wainwright went on to say in its note to investors: https://x.com/Quantumup1/status/2092953381019046000?s=20

0 · Reply

Quantumup Aug. 27 at 10:12 AM

Oppenheimer y'day⬆️ $RVMD's PT to $260 and reiterated Outperform. $IMRX $ERAS TNGX BBOT ANL VSTM Oppenheimer said -- We view today's FDA approval of RASONQUE (daraxonrasib) as a transformative event for RVMD and a landmark moment for metastatic pancreatic ductal adenocarcinoma (PDAC) based on the approved label, which exceeded investor expectations by including not only previously treated metastatic PDAC patients but also patients who are not candidates for multiagent systemic therapy, thus creating a meaningful opportunity for first-line utilization at physician discretion. The approval is supported by unprecedented Ph3 survival data, including a 60% reduction in risk of death and nearly double mOS versus chemotherapy. We increase our sales forecast, driving our new $260 price target versus $230 prior.

0 · Reply

Doozio Aug. 26 at 6:51 PM

$ERAS huckleberries n $$$ patterns ENTA 🐒🍌🧠⏰♾️

0 · Reply

spykerbob Aug. 26 at 4:05 PM

$ERAS PT 26, very bullish setp on top of EMA, RSI 60, just need some volume to blow up

0 · Reply

Cohensha Aug. 26 at 3:56 PM

$ERAS what’s happen today?, Its rise because of Moderna’s success or something else🤔?

1 · Reply

teevee Aug. 26 at 2:58 PM

$ERAS

0 · Reply

theflynews Aug. 24 at 1:07 PM

Morning Movers: Regenxbio sinks following clinical hold on RGX-121 - $ERAS - https://thefly.com/ERAS

0 · Reply

Alt_Fuel Aug. 20 at 9:04 AM

$VSTM $ERAS $RVMD GenFleet Advances First-in-World KRAS Combination Trial in Pancreatic Cancer GenFleet has initiated a three-arm phase II trial in China testing two novel GFH375-based combinations against monotherapy in KRAS G12D-mutant pancreatic cancer. The study leverages cachexia-targeting and dual RAS inhibition strategies to seek synergistic efficacy and better tolerability, strengthening GenFleet’s position in RAS-targeted oncology. - August 19, 2026 https://www.tipranks.com/news/company-announcements/genfleet-advances-first-in-world-kras-combination-trial-in-pancreatic-cancer

0 · Reply

Alt_Fuel Aug. 19 at 11:05 AM

$VSTM $ERAS $RVMD $MRNA $MRK When Oncology Science is successful ... Moderna & Merck : Intismeran Phase 3 Trial Met Primary Goal; Trial Showed Shot Prevented Melanoma Return

1 · Reply

drewskistock Aug. 17 at 5:52 PM

$ERAS

0 · Reply

Quantumup Aug. 12 at 2:12 PM

H.C. Wainwright⬆️ $ERAS to $22, reit'd Buy/said: What's new? As the RAS race continues, ERAS-0015 is now moving from an encouraging Phase 1 signal toward three potentially registration-enabling studies in pancreatic and lung cancer. $RVMD $IMRX TNGX BBOT AMGN Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2087542382992490914?s=20

0 · Reply

Market Cap	5.55B
Revenue (ttm)	0.00
Net Income (ttm)	-124.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,883,800
Avg Vol	4,094,814
Day's Range	N/A - N/A
Shares Out	349.76M
Stochastic %K	19%
Beta	0.64
Analysts	Strong Sell
Price Target	$23.67